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ABSTRACT
The Spalt-Like Transcription Factor 4 (SALL4) oncogene plays a central function 
in embryo-fetal development and is absent in differentiated tissues. Evidence suggests 
that it can be reactivated in several cancers worsening the prognosis. We aimed 
at investigating the risk associated with SALL4 reactivation for all-cause mortality 
and recurrence in cancer using the current literature. A PubMed and SCOPUS search 
until 1st September 2016 was performed, focusing on perspective studies reporting 
prognostic parameters in cancer data. In addition, 17 datasets of different cancer types 
from The Cancer Genome Atlas were considered. A total of 9,947 participants across 40 
cohorts, followed-up for about 5 years on average, were analyzed comparing patients 
showing SALL4 presence (SALL4+, n = 1,811) or absence (SALL4-, n = 8,136). All 
data were summarised using risk ratios (RRs) for the number of deaths/recurrences 
and hazard ratios (HRs) for the time-dependent risk related to SALL4+, adjusted for 
potential confounders. SALL4+ significantly increased overall mortality (RR = 1.34, 
95% confidence intervals (CI)=1.21-1.48, p<0.0001, I2=66%; HR=1.4; 95%CI: 1.19-
1.65; p<0.0001; I2=63%) and recurrence of disease (RR = 1.25, 95% CI = 1.1-1.42, 
p=0.0006, I2=62%); HR=1.52; 95% CI: 1.22-1.89, p=0.0002; I2=69%) compared to 
SALL4-. Moreover, SALL4 remained significantly associated with poor prognosis even 
using HRs adjusted for potential confounders (overall mortality: HR=1.4; 95%CI: 
1.19-1.65; p<0.0001; I2=63%; recurrence of disease: HR=1.52; 95% CI: 1.22-1.89, 
p=0.0002; I2=69%). These results suggest that SALL4 expression increases both 
mortality and recurrence of cancer, confirming this gene as an important prognostic 
marker and a potential target for personalized medicine.
INTRODUCTION
The stem-like phenotype in cancer is the result 
of epigenetic and genetic alterations leading to the 
expression of genes involved in cell migration, invasion, 
angiogenesis, self-renewal, anti-apoptosis, and immune-
escape, which are fundamental for the embryo-fetal 
development. The expression of a stem-like phenotype 
seems to play a central role in defining the malignant 
potential of different cancers. During the last decades, 
several stemness-related genes have been proposed as 
diagnostic markers for cancer, sometimes with prognostic 
significance. In particular, the fetal oncogene Spalt-Like 
Transcription Factor 4 (SALL4) has recently emerged 
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as a potential prognostic marker in many tumors. SALL4 
encodes for a zinc-finger transcription factor that plays an 
essential role during embryo-fetal development forming 
a regulatory network with other stemness-related genes, 
such as the Octamer-Binding Transcription Factor 4 
(OCT-4), the Nanog Homeobox (NANOG), and the Sex-
Determining Region Y-Box 2 (SOX2), [1–3] and then 
gradually disappears until it remains strongly silenced in 
fully differentiated tissues (except for the germline cells 
and the hematopoietic stem/progenitor cells) [4, 5].
Analyses of SALL4 expression and its epigenetic 
status as well as studies on cellular models have shown its 
oncogenic role in several tumors, such as precursor B-cell 
lymphoblastic lymphoma, acute and chronic myeloid 
leukemia, gastrointestinal, breast, and lung cancers. SALL4 
expression is generally assessed by immunohistochemistry 
(IHC) on whole section or tissue microarray (TMA), or by 
molecular testing, such as real time PCR and methylation 
analysis of the promoter region. Recently, several studies 
have proposed SALL4 as possible prognostic marker for 
cancer [6]. However, due to the lack of a comprehensive 
investigation of its prognostic value and to the different 
assessment techniques and protocols, the reliability of 
SALL4 as prognostic marker in cancer is still doubtful. 
In this work, we presented a systematic review and 
meta-analysis in order to investigate the prognostic role 
of SALL4 presence (SALL4+) in cancer patients by 
considering all-cause mortality and recurrence of cancer, 
evaluating whether SALL4+ can be associated with a 
poorer prognosis with respect to the absence of SALL4 
(SALL4-).
RESULTS
Study and patient characteristics
The bibliographic search included 175 not-redundant 
articles. After excluding 137 articles based on title/abstract 
review, 38 articles were retrieved for full text review. 
22 studies published after 2012 [7–29] were collected, 
reporting 23 independent cohorts (Supplementary 
Figure 1). The quality of the studies, assessed through 
NOS score [30], was generally good without any study 
with possible high risk of bias (Supplementary Table 1). 
Most of these 22 studies were carried out in Asia (n=18), 
three in USA, and one in Europe, mainly focusing on 
hepatocellular carcinoma (HCC) (n=11) and SALL4 was 
mainly assayed by IHC (n=18) rather than by molecular 
tests (n=6). In addition, 17 datasets of The Cancer Genome 
Atlas (TCGA) [31] were selected (see Methods section 
for additional details). All these studies were carried 
out in USA and SALL4 transcriptional activity was 
investigated by RNA sequencing technology. The selected 
TCGA datasets represent the following cancer types: 
Bladder Urothelial Carcinoma (BLCA), Breast invasive 
carcinoma (BRCA), Cervical squamous cell carcinoma 
and endocervical adenocarcinoma (CESC), Colon and 
Rectum adenocarcinoma (COADREAD), Esophageal 
carcinoma (ESCA), Glioblastoma multiforme (GBM), 
Head and Neck squamous cell carcinoma (HNSC), Kidney 
renal clear cell carcinoma (KIRC), Liver hepatocellular 
carcinoma (LIHC), Lung adenocarcinoma (LUAD), 
Lung squamous cell carcinoma (LUSC), Ovarian serous 
cystadenocarcinoma (OV), Sarcoma (SARC), Skin 
Cutaneous Melanoma (SKCM), Stomach adenocarcinoma 
(STAD), Thyroid carcinoma (THCA) and Uterine Corpus 
Endometrial Carcinoma (UCEC).
40 different cohorts were considered for the meta-
analysis, screening 9,947 patients (1,811 SALL4+ vs. 
8,136 SALL4-) with a median follow-up period of 63.75 
months (range: 7-250).
After dividing the participants by SALL4 status, 
no significant differences were found in terms of age 
(p=0.54), gender (p=0.9), tumor node metastasis (TNM) 
stage I-II percentage (p=0.21), grade (p=0.22), nodal 
(p=0.4) or vascular (p=0.31) invasion. Full descriptive 
details of all data are reported in Supplementary Tables 
2a-2b.
Risk ratios and adjusted hazard ratios for 
overall and disease-free survival
The presence of SALL4 resulted significantly 
associated with higher death rate (55.2% SALL4+ vs. 
39.8% SALL4- on average, RR=1.34; 95%CI: 1.21-
1.48, p<0.0001; I2=66%) (Figure 1a). Similar findings 
were obtained also considering the recurrence of cancer 
as outcome (26 cohorts [12, 14, 16, 17, 23, 25, 28 and 
the TCGA cohorts]; recurrence rate: 51.5% SALL4+ vs. 
42.2% SALL4-; RR=1.25; 95% CI: 1.1-1.42, p=0.0006; 
I2=62%) (Figure 1b). We then investigated the time-
dependent risk of death/recurrence in terms of hazard 
ratios (adjusted for the maximum number of the covariates 
available in each study). 25 cohorts [14, 16, 18, 19, 23, 
25, 26, 28 and the 17 TCGA cohorts] reported a survival 
analysis adjusted for a number of covariates ranging from 
1 to 14 (Supplementary Table 3).
About all-causes mortality, the pooled adjusted HR 
showed a risk of death in SALL4+ patients significantly 
higher compared to SALL4- patients (HR=1.4; 95% CI: 
1.19-1.65; p<0.0001; I2=63%) (Figure 2a). For the cancer 
recurrence, considering the available 4 studies [16, 23, 
25, 28] and the 17 TCGA cohorts, a similar result was 
obtained confirming a worse prognostic role of SALL4+ 
(HR=1.52; 95% CI: 1.22-1.89, p=0.0002; I2=69%) 
(Figure 2b).
Meta-regression, sensitivity analyses and 
publication bias
The outcomes showed high heterogeneity (as 
I2≥50%, p<0.001), therefore the effects of possible 
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Figure 1A: Forest plot of the association between associating the presence/absence of SALL4 with and all-cause 
mortality. Abbreviations: CI: Confidence Interval, SALL4: Spalt-Like Transcription Factor 4, RE: Random-Effects.
Figure 1B: Forest plot of the association between associating the presence/absence of SALL4 with recurrence of cancer. 
Abbreviations: CI: Confidence Interval, SALL4: Spalt-Like Transcription Factor 4, RE: Random-Effects.
Oncotarget22971www.impactjournals.com/oncotarget
Figure 2A: Forest plot of the association associating the presence/absence of between SALL4 with and all-cause 
mortality using the hazard ratios adjusted for the maximum number of potential confounders available in each paper. 
Abbreviations: CI: Confidence Interval, SALL4: Spalt-Like Transcription Factor 4, RE: Random-Effects.
Figure 2B: Forest plot of the association associating the presence/absence of between SALL4 with recurrence of 
cancer using the hazard ratios adjusted for the maximum number of potential confounders available in each paper. 
Abbreviations: CI: Confidence Interval, SALL4: Spalt-Like Transcription Factor 4, RE: Random-Effects.
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moderators were also considered in the meta-analysis 
models in order to check whether they can explain to some 
extent the observed heterogeneity.
In Table 1, the sensitivity analysis for pre-planned 
moderators (i.e. continent, type of cancer, method of 
assessment of SALL4) seems to poorly explain this 
heterogeneity. It is worth to stress the paucity of the 
studies for some strata (e.g. for the hazard ratio of cancer 
recurrence), which does not allow a robust assessment 
for the effect of some moderators. Table 2 reports the 
meta-regression analyses for other potential moderators: 
difference of mean age in SALL4+ vs. SALL4- patients, 
and differences of their percentages in terms of female 
number, low stage/high grade tumors, node metastases, 
vascular invasions. Follow-up period and number of 
adjustments in the survival analysis were considered as 
well. The results showed that a possible moderator for 
both relative risk and adjusted hazard ratio in all-cause 
mortality can be tumor stage (p<0.05). However, the 
residual heterogeneity test demonstrated that there should 
be also other moderators, not available for the observed 
data, able to influence the overall survival (p<0.005).
Funnel plots inspection (Figure 3) and Egger’s test 
results (Table 3) showed that the publication bias was 
Table 1: Stratification for some potential categorical moderator variables describing the association between SALL4 
and all-cause mortality or recurrence of cancer
Moderator Strata Analysis details
RR for 
all-cause 
mortality
RR for 
recurrence of 
cancer
HR for 
all-cause 
mortality
HR for 
recurrence of 
cancer
Continent Asia
Others
Pooled estimate, RR/HR 
(95%CI)
P-value for RR/HR
Heterogeneity, I2 (P-value)
Number of studies
Pooled estimate, RR/HR 
(95%CI)
P-value for RR/HR
Heterogeneity, I2 (P-value)
Number of studies
P-value *
1.42  
(1.24-1.63)
<0.0001
70 (<0.0001)
20
1.26  
(1.06-1.48)
0.0075
63 (<0.0001)
20
0.19
1.25  
(0.98-1.58)
0.07
69 (0.004)
7
1.25  
(1.07-1.47)
0.005
60 (0.0004)
19
0.96
1.71  
(1.3-2.24)
<0.0001
41 (0.12)
7
1.28  
(1.07-1.53)
0.007
57 (0.002)
18
0.08
2.46  
(1.64-3.7)
<0.0001
38 (0.2)
3
1.37  
(1.11-1.68)
0.003
57 (0.001)
18
0.02
Type of 
cancer
HCC
Others
Pooled estimate, RR/HR 
(95%CI)
P-value for RR/HR
Heterogeneity, I2 (P-value)
Number of studies
Pooled estimate, RR/HR 
(95%CI)
P-value for RR/HR
Heterogeneity, I2 (P-value)
Number of studies
P-value*
1.35  
(1.14-1.61)
0.000569 
(0.0004)
11
1.34  
(1.17-1.53)
<0.0001
67 (<0.0001)
29
0.85
1.32  
(1.03-1.69)
0.03
78 (0.0001)
7
1.2  
(1.04-1.39)
0.01
44 (0.02)
19
0.51
1.61  
(1.23-2.11)
0.0006
39 (0.15)
6
1.32  
(1.1-1.58)
0.003
58 (0.0008)
19
0.21
2.09  
(1.47-2.97)
<0.0001
12 (0.29)
2
1.45  
(1.16-1.8)
0.001
63 (0.001)
19
0.24
SALL4 
assessment
IHC
Others
Pooled estimate, RR/HR 
(95%CI)
P-value for RR/HR
Heterogeneity, I2 (P-value)
Number of studies
Pooled estimate, RR/HR 
(95%CI)
P-value for RR/HR
Heterogeneity, I2 (P-value)
Number of studies
P-value *
1.5  
(1.26-1.78)
<0.0001
77 (<0.0001)
18
1.24  
(1.09-1.4)
0.0008
52 (0.003)
22
0.12
1.5  
(1.18-1.89)
0.0008
70 (0.001)
8
1.14  
(0.99-1.32)
0.06
49 (0.01)
18
0.05
1.54  
(1.24-1.92)
0.0001
50 (0.05)
8
1.29  
(1.05-1.6)
0.02
59 (0.001)
17
0.19
1.99  
(1.14-3.47)
0.02
86 (<0.0001)
4
1.4  
(1.1-1.79)
0.006
56 (0.003)
17
0.24
* P-value represents the interaction between strata.
Abbreviations: CI: confidence interval, RR: Relative Risk, HCC: hepatocellular carcinoma, SALL4: Spalt-Like 
Transcription Factor 4, IHC: immunohistochemistry.
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unlikely across all the outcomes, except for the relative 
risk in all-cause mortality. However, the trim-and-fill 
analysis suggested that there is a low risk of publication 
bias. Moreover, the high fail-safe number for each 
outcome confirmed the significance of our findings.
DISCUSSION
SALL4 gene exerts its physiological role during 
embryo-fetal development, then gradually disappears 
and remains silenced in fully differentiated tissue, with 
the exception of germ cells and the hematopoietic stem/
progenitor cells [4, 5]. Homozygous loss-of function 
mutation of SALL4 are lethal for the embryo, while 
heterozygous mutations cause renal-ocular syndrome 
and the Okihiro syndrome, associated with multi limbs 
defects, deficient eye movements, renal malformations, 
and deafness [32]. As for OCT4, evidence suggests that 
SALL4 is a major stemness factor and both SALL4 and 
OCT4 are expressed from the 2-cells stage embryo [33]. 
Moreover, SALL4 and OCT4 form a transcriptional auto-
regulating core network, interacting with NANOG and 
SOX2 to form a multi-protein complex able to directly 
regulate both their own expression and the expression 
of hundreds of downstream target genes involved in 
pluripotency maintenance, such as Estrogen Related 
Receptor Beta (ESSRB), REST Corepressor 2 (RCOR2), 
Replication Timing Regulatory Factor 1 (RIF1) [34]. In 
addition, SALL4 complex can control gene accessibility 
recruiting the epigenetic repressor complex Mi-2/
Nucleosome Remodelling and Deacetylase (NuRD) 
involved in Phosphatase and TENsin homologue (PTEN) 
and other SALL-family genes down-regulation [35]. The 
regulation of SALL4 expression is largely unknown. 
Putative upstream regulators of SALL4 include several 
promoter activators such as the Signal Transducer and 
Activator of Transcription 3 (STAT3), the Wnt/β-catenin 
pathway, and the Caudal type homeobox 1 (CDX1) [6]. 
Epigenetic regulation of SALL4 has also been proposed, 
but it needs further confirmation. Specifically, in induced 
pluripotent stem (iPS) cells, in embryonal stem cells 
(ESCs), and in SALL4+ cancers, the expression of 
SALL4 has been related to the hypo-methylation of its 
promoter [36]. Moreover, post-transcriptional regulation 
of SALL4 has been reported and, in particular, the inverse 
relationship between miR-107 and its expression on 
human glioma [37].
Table 2: Meta-regression analysis of potential continuous moderator variables the association between SALL4 and 
all-cause mortality or recurrence of cancer
RR for all-cause 
mortality
RR for Recurrence of 
cancer
HR for all-cause 
mortality
HR for Recurrence 
of cancer
Difference in 
mean age
-0.003 (-0.02 to 0.01)
(23 studies, p=0.73)
-0.01 (-0.04 to 0.02)
(19 studies, p=0.63)
-0.02 (-0.08 to 0.04)
(18 studies, p=0.49)
-0.003 (-0.06 to 0.06)
(18 studies, p=0.91)
Difference in women 
(%)
-0.001 (-0.01 to 0.01)
(36 studies, p=0.77)
-0.003 (-0.01 to 0.01)
(26 studies, p=0.5)
0.004 (-0.01 to 0.02)
(25 studies, p=0.59)
0.01 (-0.01 to 0.03)
(21 studies, p=0.33)
Difference in TNM 
1-2 (%)
-0.01 (-0.02 to 0.001)
(30 studies, p=0.03)
-0.005 (-0.01 to 0.004)
(19 studies, p=0.3)
-0.02 (-0.03 to -0.003)
(20 studies, p=0.01)
-0.01 (-0.03 to 0.01)
(16 studies, p=0.21)
Difference in G3 (%) -0.002 (-0.01 to 0.01)
(21 studies, p=0.68)
0.01 (-0.002 to 0.01)
(13 studies, p=0.16)
0.01 (-0.002 to -0.03)
(13 studies, p=0.1)
0.01 (-0.01 to 0.03)
(11 studies, p=0.35)
Difference in nodes 
metastasis (%)
0.001 (-0.02 to 0.02)
(7 studies, p=0.96)
Few studies Few studies Few studies
Difference in vascular 
invasion (%)
-0.002 (-0.01 to 0.01)
(10 studies, p=0.73)
0.001 (-0.03 to 0.03)
(5 studies, p=0.93)
-0.01 (-0.04 to 0.02)
(5 studies, p=0.65)
Few studies
Follow-up duration 
(months)
0.002 (-4e05 to 0.004)
(39 studies, p=0.05)
-0.0001 (-0.002 to 
0.002)
(24 studies, p=0.93)
-0.003 (-0.0001 to 0.01)
(25 studies, p=0.06)
0.0002 (-0.004 to 
0.01)
(21 studies, p=0.5)
Number of 
adjustments Not applied Not applied
0.02 (-0.04 to 0.07)
(25 studies, p=0.56)
0.03 (-0.03 to 0.1)
(21 studies, p=0.34)
All differences are calculated as values in SALL4+ vs. SALL4-, except follow-up duration and number of adjustments.
The data in cells are expressed as coefficients of the meta-regression model (with 95% confidence intervals). 
Bold: significant results (p<0.05)
Abbreviations: SALL4: Spalt-Like Transcription Factor 4, RR: relative risk, HR: hazard ratio. TNM: Tumor Staging 
system, G: tumor grading.
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In cancers where aberrantly reactivated, SALL4 has 
been associated with the expression of many stemness-
related genes (i.e. OCT4, NANOG, c-Myc, and SOX2) 
conferring to the cancer cells self-renewal pluripotency 
abilities [3]. Moreover, SALL4 expression allows 
cancer cells to acquire a stem-like phenotype, including: 
1) increased mobility, invasion, and neoangiogenetic 
functions through the expression of epithelial-to-
mesenchymal transition-related genes (e.g. SNAI1, 
CXCR4, TWIST1, CDH1, Vimentin, and ZEB1) [38]; 2) 
silencing of pro-apoptotic genes (e.g PTEN); 3) inducing 
the expression of chemo-resistance-related genes (e.g. 
ATP-Binding Cassette Multidrug Transporter) [39]; 4) 
acquisition of immune evasion abilities. All the above-
mentioned features are related with the biological behavior 
of the SALL4+ cancers, which are more aggressive 
and associated with a worse prognosis compared with 
SALL4- ones. Recently, a meta-analysis showed a 
possible correlation between SALL4 expression and 
poor prognosis in cancer patients [40]. However, a large 
systematic evaluation about the role of SALL4 expression 
as prognostic marker including also the large amount of 
data available from public databases is still lacking. In this 
study, 22 perspective studies retrieved by the literature and 
17 different TCGA cohorts were considered for the meta-
analysis, involving 9,947 participants during a median 
follow-up period of about 5 years. Results showed that 
the expression of SALL4 was significantly associated 
with increased cancer mortality and recurrence, also 
after adjusting for potential confounders in the survival 
Figure 3: Funnel plots indicating that the publication bias was unlikely across all the outcomes, except for the relative 
risk in all-cause mortality.
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analyses. These findings suggest that the expression of 
this gene should be early assessed in patients. Therefore, 
the impact of SALL4 expression analysis should not be 
considered as a diagnostic and/or prognostic tool only, but 
it should be also investigated as possible target for new 
personalized treatments.
As a HCC prognostic factor, SALL4 seems to be 
particularly useful, as suggested by most of these 22 
studies (11 HCC focused) and by the large TCGA dataset 
of HCC included in our analysis. However, these studies 
were mostly performed on patients with resectable tumors, 
thus with early stage of disease, for which the survival 
is longer as demonstrated by the mean follow-up period 
of 5 years; and so far a large investigation of SALL4 
expression in advanced HCC is still lacking.
Interestingly, although SALL4 was discovered in 
1994 [41, 42], all the studies included in this study were 
published only after 2012, highlighting that its role as 
prognostic marker and possible molecular target has been 
investigated only recently. SALL4 was firstly studied in 
germline cells from solid tumors and it resulted a valid 
diagnostic marker with a good sensitivity [43], but only 
later it was associated with poor prognosis in digestive 
system cancers [18]. A main point of our study was the 
long follow-up period (5 years on average), which was 
proper to evaluate the outcomes.
From a methodological point of view, most of 
the perspective studies used IHC, the most affordable 
technique to test indirectly genes expression, especially 
for large case studies. An advantage of IHC is the 
possibility to evaluate the expression of a marker in 
the whole tumor section allowing the detection of even 
a focal positivity in heterogeneous tumors (as it could 
be for SALL4, a stemness-related marker). However, 
two studies applied IHC on tissue microarrays instead 
of whole tumor sections and the low number of tissue 
cores obtained from each tumor sample could represent 
a limitation, increasing the risk of false negative cases 
[43]. In addition, some inconsistencies emerged by 
comparing the results from IHC studies, probably related 
to the different antibodies, IHC protocols and assessment 
criteria. Consensus standardization on SALL4 IHC would 
improve the reproducibility of the results. Real time PCR 
(RT-PCR) allows a precise quantification of SALL4 
expression, although this method can be affected by tumor 
heterogeneity and it does not provide any information 
about the subcellular localization of SALL4. Looking at 
the TCGA datasets, SALL4 activity was investigated by 
RNA sequencing, which potentially allows the study of its 
expression in the entire transcriptome landscape, revealing 
possible regulative networks of SALL4 and related genes. 
However, as underlined for RT-PCR, gene expression 
could be affected by tumor heterogeneity, especially if the 
sample is not representative of the entire tumor mass. IHC, 
instead, can differently localize nuclear and cytoplasmic 
regions, allowing the detection of the position where a 
transcription factor is supposed to be active. Therefore, in 
our opinion, the best method to assess SALL4 presence in 
cancer is standardized IHC on whole tumor section.
The findings of our meta-analysis should be 
interpreted within their limitations and the most important 
of them is the inclusion of a limited number of studies. 
Secondly, through sensitivity and meta-regression analyses 
we were not able not explain the high heterogeneity found 
for the investigated outcomes. Finally, in the adjusted 
survival analyses, several important confounders (like 
cardiovascular diseases, disability, or other co-morbidities) 
were not available, further limiting the results. Despite 
these limitations, our meta-analysis suggests that SALL4 
expression shortens overall survival as well as increases 
the rate of recurrences, even taking in consideration 
potential confounders. Since many epithelial cancers are 
characterized by SALL4 reactivation, this gene should 
be considered for developing future targeted therapeutic 
strategies. Due to its prognostic value, SALL4 expression 
should be considered as potential marker in the next-
Table 3: Publication bias analysis
Outcome
Publication bias
Classic fail 
safe NEgger bias (z-score)
p value
Kendall’s tau
>p-value
Trim and fill (95% CI)
[trimmed]
RR for all cause mortality
4.15
p < 0.0001
0.31
p=0.004
1.22 (1.09-1.37)
[8] 1278
RR for recurrence of cancer
0.52
p=0.6
0.02
p=0.9
1.25 (1.1-1.42)
[0] 279
HR for all cause mortality
1.98
p=0.05
0.23
p=0.1
1.2 (0.98-1.46)
[6] 361
HR for recurrence of cancer
0.56
p=0.57
0.07
0.7
1.52 (1.22-1.89)
[0] 285
Bold: significant results (p<0.05)
Abbreviations: RR: relative risk, HR: hazard ratio, CI: confidence interval.
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generation histopathological diagnosis, hopefully by 
standardized IHC protocols, integrating cancer 
morphological features and molecular targets information 
[44–52].
MATERIALS AND METHODS
Literature search strategy
Two investigators independently conducted a 
literature search using PubMed and SCOPUS with 
no language restriction, from database inception to 1st 
September 2016, for perspective studies comparing 
relevant outcomes (i.e., all-cause mortality, cancer 
mortality and recurrence of disease/cancer) in patients 
with a diagnosis of cancer with loss vs. presence of 
expression of SALL4. In PubMed, the following search 
strategy was used: (“SALL4” OR “NM_020436”) AND 
(mortality OR mortalities OR fatality OR fatalities OR 
death* OR survival OR prognosis OR “hazard ratio” OR 
HR” OR “relative risk” OR “RR” OR “prognosis” OR 
“progression” OR “disease free survival” OR “DFS”). 
Conference abstracts and reference lists of included 
articles and those relevant to the topic were also hand-
searched for identification of additional relevant articles. 
Any inconsistencies were resolved by consensus.
Study selection and quality assessment
Newcastle-Ottawa Scale (NOS) was used to evaluate 
study quality [30]. This systematic review was performed 
following the Meta-Analysis Of Observational Studies in 
Epidemiology (MOOSE) [53] guidelines and Preferred 
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) [54] statement. Inclusion criteria 
for this meta-analysis were: 1) perspective, longitudinal 
cohort study, 2) immuno-histochemical or molecular 
investigation of SALL4 expression, 3) diagnosis of cancer, 
4) data about mortality or cancer recurrence. Exclusion 
criteria were: 1) no presence of cancer, 2) no data about 
relevant outcomes in the title/abstract, 3) no comparison 
between patients with SALL4+ vs. SALL4-, and 4) in vitro 
or animal research. To avoid overlaps between cohorts, in 
the presence of two or more studies from the same patient 
cohort, only the more recent study was taken into account 
and included in the meta-analysis.
Data extraction
Two investigators extracted key data from the 
included articles and a third independent investigator 
checked these data. For each study, information about 
authors, publication year, continent, histotype, SALL4 
assessment methods, other genes analyzed, participant 
characteristics according by SALL4 expression data 
(e.g., age, gender, tumor stage and grading, percentage of 
participants with nodal metastasis and vascular invasion), 
number and type of adjustments in survival analysis, 
and the period of follow-up. When some information 
was missing, first and/or corresponding authors of the 
original article were contacted at least four times to obtain 
unpublished data.
In addition to these studies, one investigator 
retrieved molecular and clinical data of different cancer 
types from cBioPortal for Cancer Genomics (http://
www.cbioportal.org) using the R package cgdsr version 
1.2.5 (http://cran.r-project.org/web/packages/cgdsr/index.
html). This package provides R functions for querying 
the Cancer Genomic Data Server (CGDS) hosted by the 
Computational Biology Center (cBio) at the Memorial 
Sloan-Kettering Cancer Center. For each dataset, SALL4 
expression levels from RNAseq data were downloaded as 
z-scores, representing the number of standard deviations 
from the mean of expression using tumors diploid as the 
reference population. Datasets reporting a low number of 
subjects per class for the survival analysis (i.e. less than 10 
individuals) were not considered.
Outcomes
The primary outcomes were number of deaths 
independent of the cause (all-cause mortality) and 
number of cancer recurrences during the follow-up 
period, in relation with the SALL4 presence or absence. 
The number of deaths due to cancer was preliminary 
considered as primary outcome, but no perspective study 
reported this information. As secondary outcomes, we 
considered hazard ratios (HRs) for all-cause mortality 
and recurrence, adjusted for the maximum number of 
confounders present for each study. Survival analysis was 
performed on TCGA data using the R packages survival 
version 2.39-5 (https://cran.r-project.org/web/packages/
survival/index.html). SALL4 expression was classified 
in a binary way: one class of patients was identified 
by the presence of SALL4 (SALL4+) according to an 
over-expression quantified by a z-score>=2 and the 
other class was characterized by samples reporting a 
z-score<2 (SALL4-). For each TCGA dataset, HR for all-
cause mortality and recurrence was estimated. Possible 
confounders of the final model were selected with a step-
down procedure: the decision to remove confounders 
was based on a chi-square test for goodness of fit. All 
the available confounders were first included in the full 
model considering main effects only, and then they were 
sequentially removed if their removal did not result in a 
significant change of the estimates, using a threshold of 
0.05 on the resulting p-values.
Data synthesis and statistical analysis
All statistical analyses were performed using R 
language version 3.3.0. R package metaphor version 1.9-
9 (https://cran.r-project.org/web/packages/metafor/index.
html) was used for the meta-analysis.
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Descriptive characteristics of the patients, divided 
according to the presence or absence of SALL4, were 
compared using Wilcoxon rank-sum test. In particular, 
gender, tumor stage and tumor grading were represented 
in terms of percentages of females, patients with low-
stage tumors (i.e. I-II) and patients with high-grade tumors 
(i.e. G3, G4), respectively. Vascular invasion and node 
metastasis were represented as percentages as well.
Pooled risk ratios (RRs) and adjusted hazard 
ratios (HRs) with 95% CIs were calculated for all-cause 
mortality and recurrence of cancer in patients with 
SALL4+ vs. SALL4- patients using DerSimonian-Laird 
random-effects models [55]. Heterogeneity across studies 
was assessed by the Cochrane I2 metric and chi square 
statistics. Given significant heterogeneity (p<0.05), 
meta-regression and sensitivity analyses were performed 
considering potential moderators and according to 
SALL4 status [56]. The following moderators were tested 
independently: continent (categorized as Asia vs. other 
continents), type of cancer (HCC or others), assessment 
methods (IHC or others), period of follow-up, number of 
adjustments applied in the survival model, and differences 
between SALL4+ and SALL4- participants in mean age, 
gender, tumor stage (divided in TNM stage 1-2, indicating 
low stage in percentage of SALL4+ vs. SALL4-patients), 
tumor grading (G3/G4, indicating high grade in percentage 
of SALL4+ vs. SALL4 patients), node metastasis and 
vascular invasions as percentage in SALL4+ vs. SALL4- 
patients.
Publication bias was assessed by visually inspecting 
funnel plots and using Egger’s bias test [56] and Begg-
Mazumdar Kendall tau [57]. Then, to account for 
publication bias, we used the trim-and-fill method, based 
on the assumption that the effect sizes of all the studies are 
normally distributed around the center of a funnel plot; in 
the event of asymmetries, it adjusts for the potential effect 
of unpublished (imputed) studies [58].
For all the analyses, a p-value less than 0.05 was 
considered statistically significant.
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